

09/913770

JC03 Rec'd PCT/PTO 17 AUG 2001

Attorney Docket No. 46342-56401

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Takuya Watanabe, et al.

U.S.S.N. Not Yet Assigned Art Unit: Not Yet Assigned

FILED: Filed Herewith Examiner: Not Yet Assigned

FOR: NOVEL G PROTEIN-COUPLED RECEPTOR PROTEIN AND DNA THEREOF

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Express Mail Label No. EL895420325IS. Postage prepaid, in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on August 17, 2001.

By: Louise M. Rappaport
Louise M. Rappaport

**INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE)**

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Date: August 17, 2001

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- a. ☒ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE

(check at least one box)

- a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:

- c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)

(check one box)

- a. within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

- c. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☐ No certification; therefore, a fee in the amount of \$_____ is required by 37 C.F.R. § 1.17(p).
or
b. ☐ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS;
or
b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.
c. ☐ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37

Page 4

C.F.R. § 1.56(c) more than three months prior to the filing of this statement.




Please charge Deposit Account No. 04-1105 in the amount of \$_____ for the above-indicated fee. A triplicate copy of this paper is attached.



No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.

Respectfully submitted,



Date: August 17, 2001

David G. Conlin (Reg. No. 27026)
DIKE, BRONSTEIN, ROBERTS & CUSHMAN
Intellectual Property Practice Group
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
Tel: (617) 439-4444

FORM PTO-1449				ATTY DOCKET NO.		SERIAL NO.	
INFORMATION DISCLOSURE STATEMENT				46342-56401		Not Yet Assigned	
				APPLICANT(S): Takuya Watanabe, et al.			
				FILING DATE: Filed Herewith		ART UNIT: Not Yet Assigned	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FIL. DATE IF APPR
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN YES/NO
	BA	WO96/18651	June 20, 1996	PCT			YES
	BB	EPO 899 332 A2	02/17/1998	EPO			Yes
	BC	EPO 867 508 A2	Oct. 23, 1997	EPO			Yes
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							
	CA	<i>The novel G-protein coupled receptor SALPR shares sequence similarity with somatostatin and angiotensin receptors, Matsumoto, et al., Gene 248 (2000) pp. 183-189</i>					
	CB	<i>Urotensin II Is the Endogenous Ligand of a G-Protein-Coupled Orphan Receptor, SENR (GPR14), Masaaki Mori, et al., Biochemical and Biophysical Research Communications 265, pp. 123-129 (1999)</i>					
	CC	<i>A human gene encodes a putative G protein-coupled receptor highly expressed in the central nervous system, P.J. Donohue, et al., Molecular Brain Research 54 (1998) pp. 152-160</i>					
	CD	<i>Cloning of the rat brain cDNA encoding for the SLC-1 G protein-coupled receptor reveals the presence of an intron in the gene, Bernard Lakaye, et al., Biochimica et Biophysica Acta 1401 (1998) pp. 216-220</i>					
	CE	<i>Characterization of a human gene related to genes encoding somatostatin receptors, Lee F. Kolakowski Jr., et al.; FEBS Letters 398 (1996) pp. 253-258</i>					
Examiner:				Date:			